Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 144

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 144
---
 the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, LNHC or its license partners would not be able to prevent third parties from practicing its or its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, its competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected.

Issued patents directed to the NITRICIL platform and technology could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of LNHC’s patents or patent applications (whether owned by LNHC or in-licensed from Ligand or another third party) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to its patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to its patents in such a way that any resulting protection may lead to increased competition to its business, which could harm its business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, LNHC would lose at least part, and perhaps all, of the patent protection on certain aspects of its platform technologies. In addition, if the breadth or strength of protection provided by its patents and patent applications (whether owned by LNHC or in-licensed from Ligand or another third party) is threatened, regardless of the outcome, it could dissuade companies from collaborating with LNHC to license, develop or commercialize current or future products, platform and technology.

LNHC may not be aware of all third party intellectual property rights potentially relating to its products, platform and technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. LNHC or its licensors might not have been the first to make the inventions included in